CytoSorbents Provides DrugSorb-ATR Regulatory Update

Accessibility StatementSkip Navigation PRINCETON, N.J., Sept. 16, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today provided a regulatory update on DrugSorbâ"¢-ATR. On August 20, 2025, the Company announced that it had received a U.S. Food and Drug Administration (FDA) appeal decision regarding the FDA's previous denial letter of the Company's De Novo applicat ...